Search results for " metastasis"

showing 10 items of 623 documents

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Chemotherapy of bladder tumours.

1978

OncologyNephrologymedicine.medical_specialtyChemotherapyBladder cancerPapillomabusiness.industryUrologymedicine.medical_treatmentBLADDER PAPILLOMAAntineoplastic Agentsmedicine.diseaseTopical chemotherapyCarcinoma PapillaryUrinary Bladder NeoplasmsRecurrenceInternal medicineChemoprophylaxisMedicineHumansNeoplasm MetastasisbusinessCarcinoma in SituThiotepaTeniposideUrological research
researchProduct

Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic …

2015

Abstract Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). Experimental Design: Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) we…

OncologyNeuroblastoma RAS viral oncogene homologAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyColorectal cancerPopulationDNA Mutational AnalysisLeucovorinmedicine.disease_causeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicinePanitumumabHumansNeoplasm MetastasiseducationAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studybusiness.industryPanitumumabCancerAntibodies MonoclonalExonsMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesIrinotecanGenes rasTreatment OutcomeOncologyMutationRetreatmentFOLFIRICamptothecinFemaleKRASFluorouracilHuman medicinebusinessColorectal Neoplasmsmedicine.drugClinical cancer research
researchProduct

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?

2015

Abstract: Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid b…

OncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtyColorectal cancerDrug ResistanceCetuximabAntineoplastic AgentsReviewGene mutationCetuximab; Colorectal cancer; Epidermal growth factor receptor; Panitumumab; RAS; Oncologymedicine.disease_causeAntibodiesGTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Internal medicineMonoclonalmedicinePanitumumabHumansEpidermal growth factor receptorLiquid biopsyNeoplasm MetastasisBiologyneoplasmsbiologyCetuximabEpidermal Growth FactorEpidermal growth factor receptorPanitumumabAntibodies MonoclonalMembrane Proteinsmedicine.diseaseCetuximab; Colorectal cancer; Epidermal growth factor receptor; Panitumumab; RAS; Antibodies Monoclonal; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Resistance Neoplasm; GTP Phosphohydrolases; Humans; Membrane Proteins; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; OncologyColorectal cancerErbB ReceptorsOncologyDrug Resistance NeoplasmMutationCancer researchbiology.proteinNeoplasmHuman medicineKRASColorectal Neoplasmsmedicine.drugReceptorRAS
researchProduct

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders

2021

OncologyPeritoneal metastasismedicine.medical_specialtyColonic NeoplasmStagingColorectal cancerbusiness.industryConfoundingGeneral Medicinemedicine.diseaseColon cancerPeritoneal invasionOncologyTumour cellHomogeneousInternal medicinemedicineLocal recurrencePeritoneal metastasiSurgeryPeritoneumbusinessPeritoneal NeoplasmsHuman
researchProduct

Intraoperative Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients with Locally Advanced Colon Cancer: A Prospective Parallel Phase II Stu…

2020

.Background: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in patients with colorectal carcinoma at high risk of recurrence but still without clinically and radiologically evident signs of peritoneal spread. This study aims to analyze the feasibility of this proactive, early phase, multimodality approach. Methods: A mono-institutional, prospective, parallel, two-stage phase II trial enrolled 49 patients to standard surgery or surgery plus intraoperative HIPEC. Before the procedure and during surgery, patients received intravenous fluorouracil (and leucovorin to potentiate oxaliplatin activity. Data analysis included length of hospital stay, surgery …

OncologyPeritoneal metastasismedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentLocally advancedPhases of clinical researchmedicine.diseaseText miningInternal medicinemedicineIn patientHyperthermic intraperitoneal chemotherapybusinessAdjuvantoncology_oncogenics
researchProduct

Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.

2019

In prostate adenocarcinoma (PCa), distinction between indolent and aggressive disease is challenging. Around 50% of PCa are characterized by TMPRSS2‐ERG (T2E)‐fusion oncoproteins defining two molecular subtypes (T2E‐positive/negative). However, current prognostic tests do not differ between both molecular subtypes, which might affect outcome prediction. To investigate gene‐signatures associated with metastasis in T2E‐positive and T2E‐negative PCa independently, we integrated tumor transcriptomes and clinicopathological data of two cohorts (total n = 783), and analyzed metastasis‐associated gene‐signatures regarding the T2E‐status. Here, we show that the prognostic value of biomarkers in PCa…

OncologyProstate adenocarcinomaMaleCancer Researchmedicine.medical_specialtyOncogene Proteins FusionKaplan-Meier EstimateAdenocarcinomaTMPRSS2MetastasisTranscriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorHumansPrognostic biomarkerMetastasis ; Personalized Medicine ; Prognostic Biomarker ; Prostate Adenocarcinoma ; Tmprss2-ergNeoplasm MetastasisNeoplasm Stagingbusiness.industryGene Expression ProfilingComputational BiologyProstatic Neoplasmsmedicine.diseasePrognosisImmunohistochemistryGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisImmunohistochemistryPersonalized medicineNeoplasm GradingbusinessErgInternational journal of cancerReferences
researchProduct

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

2014

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost–effectiveness involved with the use of the drug.

OncologySettore MED/06 - Oncologia MedicaCost effectivenessColorectal cancercost-effectiveneCetuximabColorectal NeoplasmPharmacologyAntineoplastic AgentPhosphatidylinositol 3-KinasesMutational statusMedicineNeoplasm MetastasiscetxuximabProto-Oncogene ProteinTOR Serine-Threonine KinaseCetuximabPharmacogeneticTOR Serine-Threonine KinasesNeoplasm MetastasiErbB ReceptorsMolecular MedicineColorectal NeoplasmsHumanmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtypharmacogenomicEGFRAntineoplastic AgentsAntibodies Monoclonal HumanizedresistanceProto-Oncogene Proteins p21(ras)Geneticcolorectal carcinomaProto-Oncogene ProteinsInternal medicineGeneticsHumanspredictivecost-effectivenessneoplasmspharmacogenomicsPharmacologybusiness.industryPTEN Phosphohydrolaseras Proteinmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsMutationras ProteinsReceptor Epidermal Growth FactorPhosphatidylinositol 3-KinasebusinessProto-Oncogene Proteins c-aktPharmacogeneticsRASPharmacogenomics
researchProduct

Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations

2014

Background: The aim of this retrospective study was to investigate the incidence of mesenteric lymph node (MLN) involvement, and its prognostic role in advanced ovarian cancer (OC). Methods: OC patients undergoing rectosigmoid resection during primary debulking surgery or interval debulking surgery were recorded. Progression-free survival (PFS) and overall survival were calculated from the date of diagnosis to the date of relapse/progression, death of disease, or the date of last follow-up. Results: MLNs were detected in 102/148 cases (68.9 %); the rate of MLN involvement was 47.0 %. The percentage of metastatic MLNs was higher in cases with >5 MLNs removed compared with cases with ≤5 MLNs …

OncologySettore MED/18 - CHIRURGIA GENERALEGastroenterologyClear CellSurgical oncology80 and overMucinousMesenteryCystadenocarcinomaLymph nodeAged 80 and overOvarian NeoplasmsMedicine (all)Middle AgedDebulkingPrognosisAdenocarcinoma MucinousOVARIAN CANCERSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisAdenocarcinomaFemaleAdultmedicine.medical_specialtyCystadenocarcinomaAdenocarcinomaAdenocarcinoma Clear Cell; Adenocarcinoma Mucinous; Adult; Aged; Aged 80 and over; Cystadenocarcinoma Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mesentery; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Rectum; Retrospective Studies; Sigmoid Neoplasms; Survival Rate; Surgery; OncologyInternal medicinemedicineHumansSurvival rateAgedRetrospective Studiesbusiness.industryRectumSerousRetrospective cohort studymedicine.diseaseCystadenocarcinoma SerousEndometrial NeoplasmsSigmoid NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIALymph Node ExcisionSurgeryLymph NodesNeoplasm GradingOvarian cancerbusinessAdenocarcinoma Clear CellFollow-Up Studies
researchProduct